Scholarlink

<p>The adipokine chemerin is increased in the serum of individuals with obesity and type 2 diabetes. Patients with type 2 diabetes exhibit a threefold increased risk of developing tuberculosis, are more refractory to tuberculosis treatment and display more severe forms of the disease. Patients with type 2 diabetes and tuberculosis exhibit a dysfunctional immunological response characterized by a higher frequency of peripheral Th1 and Th17 cells, increased concentrations of pro- and anti-inflammatory cytokines, and a reduced microbicidal capacity compared to subjects affected exclusively by tuberculosis. In the present study, we investigated whether chemerin exerts a pro- or anti-inflammatory effect on macrophages in vitro and its role in the lungs of normoglycemic or hyperglycemic (obese plus type 2 diabetes) mice infected with <i>Mycobacterium tuberculosis</i>. Bone marrow-derived macrophages (BMDM) cultured with hyperglycemic medium and infected with <i>M. tuberculosis</i> secreted increased IL-6 and reduced IL-10 concentrations following chemerin treatment. BMDM from obese (fed with high-fat diet, HFD), non-diabetic mice were also pro-inflammatory, while BMDM from obese and diabetic mice (db/db) showed no significant difference compared to BMDM from normoglycemic mice (db/+). In vivo, db/db mice exhibited an increase of bacterial load and an exacerbated pulmonary immunopathology. Treatment of infected db/db mice with CCX832 chemerin receptor (ChemR23) antagonist significantly reduced pulmonary inflammation with no effect on bacterial load. Our findings show that blocking chemerin receptors may represent an adjuvant therapeutic strategy to mitigate pulmonary immunological response-mediated pathology accentuated by type 2 diabetes in active tuberculosis.</p> Graphical Abstract <p>Type 2 diabetes causes more severe forms of tuberculosis and is associated with high levels of adipokine chemerin. The role of chemerin in tuberculosis remains unclear. Corrêa <i>et al.</i> describe that chemerin is pro-inflammatory in bone marrow-derived macrophages (BMDM) cultivated in high-glucose conditions and infected with <i>M. tuberculosis</i>. The treatment of type 2 diabetic mice infected with<i> M. tuberculosis</i> with CCX832 chemerin receptor antagonist ameliorates pulmonary inflammation.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chemerin Exacerbates Pulmonary Inflammation in Type 2 Diabetes and Mycobacterium Tuberculosis Infection Comorbidity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月22日

查看全文
  • Giseli Furlan Corrêa,
  • Núbia Sabrina Martins,
  • Ualter Guilherme Cipriano,
  • Ana Flávia Gembre,
  • Daniel Rodrigues,
  • Vinícius Bottura Apolloni,
  • Leandra Naira Zambelli Ramalho,
  • Thais Fernanda de Campos Fraga-Silva,
  • Rita Tostes,
  • Vânia Luiza Deperon Bonato

摘要

The adipokine chemerin is increased in the serum of individuals with obesity and type 2 diabetes. Patients with type 2 diabetes exhibit a threefold increased risk of developing tuberculosis, are more refractory to tuberculosis treatment and display more severe forms of the disease. Patients with type 2 diabetes and tuberculosis exhibit a dysfunctional immunological response characterized by a higher frequency of peripheral Th1 and Th17 cells, increased concentrations of pro- and anti-inflammatory cytokines, and a reduced microbicidal capacity compared to subjects affected exclusively by tuberculosis. In the present study, we investigated whether chemerin exerts a pro- or anti-inflammatory effect on macrophages in vitro and its role in the lungs of normoglycemic or hyperglycemic (obese plus type 2 diabetes) mice infected with Mycobacterium tuberculosis. Bone marrow-derived macrophages (BMDM) cultured with hyperglycemic medium and infected with M. tuberculosis secreted increased IL-6 and reduced IL-10 concentrations following chemerin treatment. BMDM from obese (fed with high-fat diet, HFD), non-diabetic mice were also pro-inflammatory, while BMDM from obese and diabetic mice (db/db) showed no significant difference compared to BMDM from normoglycemic mice (db/+). In vivo, db/db mice exhibited an increase of bacterial load and an exacerbated pulmonary immunopathology. Treatment of infected db/db mice with CCX832 chemerin receptor (ChemR23) antagonist significantly reduced pulmonary inflammation with no effect on bacterial load. Our findings show that blocking chemerin receptors may represent an adjuvant therapeutic strategy to mitigate pulmonary immunological response-mediated pathology accentuated by type 2 diabetes in active tuberculosis.

Graphical Abstract

Type 2 diabetes causes more severe forms of tuberculosis and is associated with high levels of adipokine chemerin. The role of chemerin in tuberculosis remains unclear. Corrêa et al. describe that chemerin is pro-inflammatory in bone marrow-derived macrophages (BMDM) cultivated in high-glucose conditions and infected with M. tuberculosis. The treatment of type 2 diabetic mice infected with M. tuberculosis with CCX832 chemerin receptor antagonist ameliorates pulmonary inflammation.